Australia’s first true biotech incubator

Proto Axiom is an incubation firm with an investment arm. This structure provides us with the flexibility to construct a portfolio of the best, most innovative businesses in biotechnology.

Medical innovation, funding, and pre-clinical research with strong financial returns.

From early-stage funding to growth capital, we guide scientific breakthroughs from proof-of-concept to commercial success. Our hands-on approach to support Australian research is a first-in-country model.

We know first hand how to build world-class companies. Proto Axiom on-shores scientific capacity backed by leading institutional investors to keep IP in Australia.

Endo Axiom (Endo) is a cutting-edge platform technology harnessing liver-specific nanoparticles, set to revolutionise diabetes treatment.

Established by esteemed academics from the University of Sydney and Sydney Local Health District, Endo Axiom secured a $2.2 million investment from Proto Axiom. As a proud member of the Proto Axiom family, Endo benefits from comprehensive commercial, technical, and financial support from Proto.

Dr. Nicholas Hunt, CEO of Endo, holds a Senior Lecturer position at Concord Clinical School and is a recipient of the MRFF Targeted Translation Research Accelerator (TTRA) and Sydney Research Accelerator (SOAR) awards. Joining him in this venture are co-founders Prof. David Le Couteur AO and Prof. Victoria Cogger, with Lawrence Gozlan presiding as Chairman.

Dr. Nicholas Hunt
CEO and Co-founder

A spin-out from the University of New South Wales, Swan Genomics was founded in 2023 by academic founders Dr. Lawrence Lee and Min Huang, together with highly regarded US-based industry experts, Dr. Brock Siegel and Dr. Bill Hyun. Swan Genomics has secured $2m in funding from Proto Axiom, and benefits from the full suite of Proto Axiom’s incubation services.

Lawrence Lee is a Chief Investigator at the ARC Centre of Excellence in Synthetic Biology and Associate Professor at the Department of Molecular Medicine, at the University of New South Wales. He was awarded his PhD from the University of Sydney before undertaking a postdoctoral position at the Victor Chang Cardiac Research Institute and an European Molecular Biology Organisation Fellowship at the University of Oxford. He has been recognised numerous awards and honours including an ARC Discovery Early Career Research Award, the National Association of Research Fellows Young Investigator of the Year and a NSW Tall Poppy Award.

Dr. Lawrence Lee
CEO and Co-founder

Australia produces world leading intellectual property in drug development and medical devices, yet captures virtually none of the downstream economics and job multipliers.

Proto Axiom on shores capacity, keeping Australian IP in Australia.